Phase 3 trial of combination for advanced lung cancer misses co-primary endpoint

A randomized phase 3 trial designed to evaluate tiragolumab plus atezolizumab for certain patients with advanced lung cancer failed to meet its co-primary endpoint of PFS, topline data showed.
Data for the other co-primary endpoint of OS remained immature, and the study will continue until the next planned analysis.
Tiragolumab (Genentech/Roche) is an immunotherapy designed to bind to TIGIT, a protein receptor on immune cells. Atezolizumab (Tecentriq, Genentech/Roche) is an anti-PD-L1 therapy.
The global double-blind SKYSCRAPER-01 study included 534 patients with PD-L1-high locally advanced

A randomized phase 3 trial designed to evaluate tiragolumab plus atezolizumab for certain patients with advanced lung cancer failed to meet its co-primary endpoint of PFS, topline data showed.
Data for the other co-primary endpoint of OS remained immature, and the study will continue until the next planned analysis.
Tiragolumab (Genentech/Roche) is an immunotherapy designed to bind to TIGIT, a protein receptor on immune cells. Atezolizumab (Tecentriq, Genentech/Roche) is an anti-PD-L1 therapy.
The global double-blind SKYSCRAPER-01 study included 534 patients with PD-L1-high locally advanced